Circulating biosignatures in multiple myeloma and their role in multidrug resistance
Abstract A major obstacle to chemotherapeutic success in cancer treatment is the development of drug resistance. This occurs when a tumour fails to reduce in size after treatment or when there is clinical relapse after an initial positive response to treatment. A unique and serious type of resistanc...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-04-01
|
| Series: | Molecular Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12943-022-01683-w |
| _version_ | 1797836532970684416 |
|---|---|
| author | S. Rajeev Krishnan M. Bebawy |
| author_facet | S. Rajeev Krishnan M. Bebawy |
| author_sort | S. Rajeev Krishnan |
| collection | DOAJ |
| description | Abstract A major obstacle to chemotherapeutic success in cancer treatment is the development of drug resistance. This occurs when a tumour fails to reduce in size after treatment or when there is clinical relapse after an initial positive response to treatment. A unique and serious type of resistance is multidrug resistance (MDR). MDR causes the simultaneous cross resistance to unrelated drugs used in chemotherapy. MDR can be acquired through genetic alterations following drug exposure, or as discovered by us, through alternative pathways mediated by the transfer of functional MDR proteins and nucleic acids by extracellular vesicles (M Bebawy V Combes E Lee R Jaiswal J Gong A Bonhoure GE Grau, 23 9 1643 1649, 2009). Multiple myeloma is an incurable cancer of bone marrow plasma cells. Treatment involves high dose combination chemotherapy and patient response is unpredictable and variable due to the presence of multisite clonal tumour infiltrates. This clonal heterogeneity can contribute to the development of MDR. There is currently no approved clinical test for the minimally invasive testing of MDR in myeloma. Extracellular vesicles comprise a group of heterogeneous cell-derived membranous structures which include; exosomes, microparticles (microvesicles), migrasomes and apoptotic bodies. Extracellular vesicles serve an important role in cellular communication through the intercellular transfer of cellular protein, nucleic acid and lipid cargo. Of these, microparticles (MPs) originate from the cell plasma membrane and vary in size from 0.1-1um. We have previously shown that MPs confer MDR through the transfer of resistance proteins and nucleic acids. A test for the early detection of MDR would benefit clinical decision making, improve survival and support rational drug use. This review focuses on microparticles as novel clinical biomarkers for the detection of MDR in Myeloma and discusses their role in the therapeutic management of the disease. |
| first_indexed | 2024-04-09T15:11:32Z |
| format | Article |
| id | doaj.art-27c2410fc62c46c59f1f5738cf6d1f96 |
| institution | Directory Open Access Journal |
| issn | 1476-4598 |
| language | English |
| last_indexed | 2024-04-09T15:11:32Z |
| publishDate | 2023-04-01 |
| publisher | BMC |
| record_format | Article |
| series | Molecular Cancer |
| spelling | doaj.art-27c2410fc62c46c59f1f5738cf6d1f962023-04-30T11:09:20ZengBMCMolecular Cancer1476-45982023-04-0122111410.1186/s12943-022-01683-wCirculating biosignatures in multiple myeloma and their role in multidrug resistanceS. Rajeev KrishnanM. BebawyAbstract A major obstacle to chemotherapeutic success in cancer treatment is the development of drug resistance. This occurs when a tumour fails to reduce in size after treatment or when there is clinical relapse after an initial positive response to treatment. A unique and serious type of resistance is multidrug resistance (MDR). MDR causes the simultaneous cross resistance to unrelated drugs used in chemotherapy. MDR can be acquired through genetic alterations following drug exposure, or as discovered by us, through alternative pathways mediated by the transfer of functional MDR proteins and nucleic acids by extracellular vesicles (M Bebawy V Combes E Lee R Jaiswal J Gong A Bonhoure GE Grau, 23 9 1643 1649, 2009). Multiple myeloma is an incurable cancer of bone marrow plasma cells. Treatment involves high dose combination chemotherapy and patient response is unpredictable and variable due to the presence of multisite clonal tumour infiltrates. This clonal heterogeneity can contribute to the development of MDR. There is currently no approved clinical test for the minimally invasive testing of MDR in myeloma. Extracellular vesicles comprise a group of heterogeneous cell-derived membranous structures which include; exosomes, microparticles (microvesicles), migrasomes and apoptotic bodies. Extracellular vesicles serve an important role in cellular communication through the intercellular transfer of cellular protein, nucleic acid and lipid cargo. Of these, microparticles (MPs) originate from the cell plasma membrane and vary in size from 0.1-1um. We have previously shown that MPs confer MDR through the transfer of resistance proteins and nucleic acids. A test for the early detection of MDR would benefit clinical decision making, improve survival and support rational drug use. This review focuses on microparticles as novel clinical biomarkers for the detection of MDR in Myeloma and discusses their role in the therapeutic management of the disease.https://doi.org/10.1186/s12943-022-01683-wBiomarkers, Extracellular vesicles, Liquid biopsy, Microparticles, Multidrug resistance multiple myeloma, Personalized medicine |
| spellingShingle | S. Rajeev Krishnan M. Bebawy Circulating biosignatures in multiple myeloma and their role in multidrug resistance Molecular Cancer Biomarkers, Extracellular vesicles, Liquid biopsy, Microparticles, Multidrug resistance multiple myeloma, Personalized medicine |
| title | Circulating biosignatures in multiple myeloma and their role in multidrug resistance |
| title_full | Circulating biosignatures in multiple myeloma and their role in multidrug resistance |
| title_fullStr | Circulating biosignatures in multiple myeloma and their role in multidrug resistance |
| title_full_unstemmed | Circulating biosignatures in multiple myeloma and their role in multidrug resistance |
| title_short | Circulating biosignatures in multiple myeloma and their role in multidrug resistance |
| title_sort | circulating biosignatures in multiple myeloma and their role in multidrug resistance |
| topic | Biomarkers, Extracellular vesicles, Liquid biopsy, Microparticles, Multidrug resistance multiple myeloma, Personalized medicine |
| url | https://doi.org/10.1186/s12943-022-01683-w |
| work_keys_str_mv | AT srajeevkrishnan circulatingbiosignaturesinmultiplemyelomaandtheirroleinmultidrugresistance AT mbebawy circulatingbiosignaturesinmultiplemyelomaandtheirroleinmultidrugresistance |